paritaprevir
Sign in to saveParitaprevir (previously known as ABT-450) is an acylsulfonamide inhibitor of the NS3-4A serine protease manufactured by Abbott Laboratories that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1. Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3.
Key facts
- Drug.IUPAC_name
- (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-{[(5-methyl-2-pyrazinyl)carbonyl]amino}-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo [1,2-a] [1,4]diazacyclopentadecine-14a(5H)-carboxamide
- Drug.image
- File:Paritaprevir structure 2.svg
- Drug.width
- 285
- Drug.tradename
- Viekira Pak (in combination with ombitasvir, ritonavir and dasabuvir), Technivie/Viekirax (in combination with ombitasvir and ritonavir)
- Drug.pregnancy_US
- B
- Drug.licence_EU
- yes
- Drug.legal_US
- Rx-only
- Drug.routes_of_administration
- Oral
- Drug.bioavailability
- was not evaluated
- Drug.protein_bound
- 97–98.6%
- Drug.metabolism
- Hepatic, CYP3A4 and CYP3A5
- Drug.onset
- 4 to 5 hours
- Drug.elimination_half life
- 5.5 hours
- Drug.excretion
- feces (88%), urine (8,8%)
- Drug.CAS_number
- 1216941-48-8
- Drug.UNII
- OU2YM37K86
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AP52
via Wikipedia infobox
Chemical data
- Formula
- C40H43N7O7S
- Molecular weight
- 765.9 g/mol
- IUPAC name
- (1S,4R,6R,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide
via PubChem
Article
1 sectionsContents
- References
{{Infobox drug | drug_name = | IUPAC_name = (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-{[(5-methyl-2-pyrazinyl)carbonyl]amino}-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo [1,2-a] [1,4]diazacyclopentadecine-14a(5H)-carboxamide | image = File:Paritaprevir structure 2.svg | width = 285 | alt = | caption =
| tradename = Viekira Pak (in combination with ombitasvir, ritonavir and dasabuvir), Technivie/Viekirax (in combination with ombitasvir and ritonavir) | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = B | pregnancy_category = | licence_EU = yes | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Oral